CHMP recommends licence extension for burosumab (Crysvita)
This product licence for burosumab, is now intended to include use in adult patients, for the treatment of X-linked hypophosphataemia.
Source:
European Medicines Agency
This product licence for burosumab, is now intended to include use in adult patients, for the treatment of X-linked hypophosphataemia.
European Medicines Agency